Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of 5-Fluorouridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 2/20 | 0.68 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.68 |
| ▸ | NT5E | P21589 | 1/20 | 0.68 |
| ▸ | PYGM | P11217 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | HBB | P68871 | 1/20 | 0.62 |
| ▸ | TK2 | O00142 | 2/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.57 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.56 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.55 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.55 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.55 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 5-Fluorouridine SCHEMBL668873 | 1.00 | P2RY6 (0.68) | P2RY6P2RY14NT5EPYGMLMNA | |
| 5-Fluorouridine SCHEMBL19901621 | 0.95 | PYGM (0.70) | P2RY6P2RY14NT5EPYGMLMNA | |
| 5-Fluorouridine SCHEMBL3385435 | 0.95 | PYGM (0.70) | P2RY6P2RY14NT5EPYGMLMNA | |
| 5-Fluorouridine SCHEMBL1682759 | 0.95 | PYGM (0.70) | P2RY6P2RY14NT5EPYGMLMNA | |
| 5-Fluorouridine SCHEMBL329381 | 0.95 | PYGM (0.70) | P2RY6P2RY14NT5EPYGMLMNA | |
| 5-Fluorouridine SCHEMBL12174049 | 0.95 | PYGM (0.70) | P2RY6P2RY14NT5EPYGMLMNA | |
| 5-Fluorouridine SCHEMBL11756887 | 0.95 | PYGM (0.70) | P2RY6P2RY14NT5EPYGMLMNA | |
| 5-Fluorouridine SCHEMBL17173362 | 0.95 | PYGM (0.70) | P2RY6P2RY14NT5EPYGMLMNA | |
| 5-Fluorouridine SCHEMBL21423048 | 0.95 | PYGM (0.70) | P2RY6P2RY14NT5EPYGMLMNA | |
| 5-Fluorouridine SCHEMBL214536 | 0.95 | PYGM (0.70) | P2RY6P2RY14NT5EPYGMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935331-B1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | ABBVIE INC (US) | 2018-02-28 | — | — | EP | claimed |
| EP-2935331-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | AbbVie Inc. (US) | 2015-10-28 | — | — | EP | claimed |
| US-20140227294-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | ABBVIE INC. (US) | 2014-08-14 | — | — | US | claimed |
| WO-2014105810-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | ABBVIE INC. (US) | 2014-07-03 | — | — | WO | claimed |
| US-12551570-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2026-02-17 | — | — | US | disclosed |
| US-12479927-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-20250186435-A1 | PHARMACEUTICAL FORMULATIONS AND THEIR PREPARATIONS FOR TREATMENT OF CANCER | CELLIX BIO PRIVATE LIMITED (IN) | 2025-06-12 | — | — | US | disclosed |
| US-20250163159-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250121087-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES | INTOCELL, INC. (KR) | 2025-04-17 | — | — | US | disclosed |
| US-12168060-B2 | Antibody-drug conjugates comprising anti-B7-H3 antibodies | INTOCELL, INC. (KR) | 2024-12-17 | — | — | US | disclosed |
| WO-2024187069-A1 | ENGINEERING ENTEROBACTERIA TO SITE-SPECIFICALLY ACTIVATE THE ANTICANCER PRODRUG 5-FLUOROCYTOSINE FOR TREATING COLON CANCER | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-09-12 | — | — | WO | disclosed |
| CN-111378041-B | Anti-EGFR antibodies and antibody drug conjugates | 艾伯维公司 | 2024-08-02 | — | — | CN | disclosed |
| US-5736531-A | ADMINISTERING TO TREAT AND PREVENT TOXICITY | PRO-NEURON, INC. (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0831855-A1 | NUCLEOTIDE ANALOGUES FOR TOPICAL TREATMENT OF PROLIFERATIVE DISEASE OF THE SKIN | HOSTETLER, Karl Y. (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0831849-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5667989-A | Fungal cell wall Protein CLY4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-09-16 | — | — | US | disclosed |
| US-5654286-A | Nucleotides for topical treatment of psoriasis, and methods for using same | HOSTETLER KARL Y (US) | 1997-08-05 | — | — | US | disclosed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040166-A1 | NUCLEOTIDE ANALOGUES FOR TOPICAL TREATMENT OF PROLIFERATIVE DISEASE OF THE SKIN | HOSTETLER KARL Y (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1994026761-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227294-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | PRLHR, LHCGR, FCGR2A | P2RY6 2607/4885P2RY14 2273/4885NT5E 1158/4885 |
| US-20250121087-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES | CD274, CD44, H1-3 | P2RY6 3161/4885P2RY14 3560/4885NT5E 880/4885 |
| US-12551570-B2 | Compounds comprising cleavable linker and uses thereof | FCGR2A, FCGR3B, FCGR1A | P2RY6 3005/4885P2RY14 3131/4885NT5E 1008/4885 |
| US-12168060-B2 | Antibody-drug conjugates comprising anti-B7-H3 antibodies | CD274, CD44, H1-3 | P2RY6 3161/4885P2RY14 3560/4885NT5E 880/4885 |
| US-12479927-B2 | Compounds comprising cleavable linker and uses thereof | VIP, ANTXR2, TNFRSF9 | P2RY6 823/4885P2RY14 547/4885NT5E 1350/4885 |
| US-20250163159-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | P2RY6 3359/4885P2RY14 3786/4885NT5E 256/4885 |
| US-20250186435-A1 | PHARMACEUTICAL FORMULATIONS AND THEIR PREPARATIONS FOR TREATMENT OF CANCER | SLC5A1, DPYD, SLC46A1 | P2RY6 281/4885P2RY14 1240/4885NT5E 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.